$BAYN Bayer has discontinued development of its 2nd P2X3 antagonist in chronic cough (Phase 2) and other indications (Phase 1), per its 1Q'20 earnings presentation.

$MRK $BLU $SGIOY https://t.co/TVSfDIjKg3